This transition is typically associated with an increase in the regularity and frequency of use [47]
Microdosing sits below that ramp
Reevaluate metabolic status prior to discontinuing and restarting GLP-1 therapy, measure HbA1c, electrolytes, and fasting glucose and document any insulin requirements to assist in safe resumption
Phase 4: the 1.7mg acceleration dose (34 units) The jump from 1.0mg to 1.7mg is the largest single escalation in the standard protocol, a 0.7mg increase compared to the 0.25mg and 0.5mg jumps earlier
Researchers theorize this may be because: GIP activation may counterbalance some GLP-1 effects on the gut Dose escalation schedule allows more gradual adaptation Different pharmacokinetic profile may produce less pronounced peaks Serious Side Effects (Both Medications): These are rare but require immediate medical attention: Pancreatitis: Severe abdominal pain that may radiate to the back Risk: Less than 1% with both medications Usually occurs in first few months of treatment Requires immediate discontinuation if suspected Gallbladder Problems: Gallstones, cholecystitis (gallbladder inflammation) Symptoms: Right upper abdominal pain, nausea, fever More common with rapid weight loss May require surgical intervention Kidney Problems: Dehydration from vomiting/diarrhea can affect kidney function Watch for decreased urination, swelling in legs Stay well-hydrated, especially during side effect periods Thyroid Tumors (Black Box Warning): Both medications carry warnings about thyroid C-cell tumors Based on rodent studies
